GlycoMimetics (NASDAQ:GLYC) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Monday, February 4th.
A number of other analysts have also commented on the stock. Roth Capital set a $35.00 price objective on shares of GlycoMimetics and gave the company a “buy” rating in a research note on Monday, November 5th. BidaskClub upgraded GlycoMimetics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Zacks Investment Research cut GlycoMimetics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 30th. Finally, HC Wainwright began coverage on GlycoMimetics in a research report on Tuesday, December 18th. They set a “buy” rating and a $24.00 target price for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $23.75.
GlycoMimetics stock traded up $0.13 during trading on Monday, reaching $11.21. The company had a trading volume of 362 shares, compared to its average volume of 253,879. GlycoMimetics has a 12-month low of $8.29 and a 12-month high of $26.05. The company has a market cap of $477.96 million, a price-to-earnings ratio of -9.91 and a beta of 2.82.
Large investors have recently bought and sold shares of the business. Prentiss Smith & Co. Inc. increased its position in shares of GlycoMimetics by 42.9% in the 4th quarter. Prentiss Smith & Co. Inc. now owns 10,000 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 3,000 shares during the last quarter. WINTON GROUP Ltd acquired a new position in GlycoMimetics during the third quarter valued at approximately $186,000. Voya Investment Management LLC acquired a new stake in GlycoMimetics in the second quarter valued at $205,000. Virtus ETF Advisers LLC increased its stake in GlycoMimetics by 3.7% during the fourth quarter. Virtus ETF Advisers LLC now owns 29,862 shares of the biotechnology company’s stock valued at $283,000 after purchasing an additional 1,057 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in GlycoMimetics by 44.2% in the third quarter. Alliancebernstein L.P. now owns 22,500 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 6,900 shares during the period.
GlycoMimetics Company Profile
GlycoMimetics, Inc, a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc The company’s drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma.
Featured Story: Stock Selection – What is cash flow?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for GlycoMimetics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GlycoMimetics and related companies with MarketBeat.com’s FREE daily email newsletter.